Expression of bcl-2, bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: Relationship with apoptosis and proliferation

Prostate

Volumn 37, Issue 4, 1998, Pages 223-229

  Johnson, Mark I ^a   Robinson, Mary C ^b   Marsh, Colin ^b   Robson, Craig N ^a   Neal, David E ^a   Hamdy, Freddie C ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; High grade prostatic intraepithelial neoplasia; Ki 67; P53

Indexed keywords

ANDROGEN; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTO ONCOGENE;

ANDROGENS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; HUMANS; KI-67 ANTIGEN; MALE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031757941     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19981201)37:4<223::AID-PROS3>3.0.CO;2-O     Document Type: Article

References (49)

1. Bostwick DG: High grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Cancer 1995;75: 1823-1836.
2. Haggman MJ, Macoska JA, Wojna KJ, Oesterling JE: The relationship between prostatic intraepithelial neoplasia and prostate cancer: Critical issues. J Urol 1997;158:12-22.
3. Bostwick DG, Pacelli A, Lopez-Beltran A: Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996;29:117-134.
4. Bostwick DG: Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996;78:330-336.
5. Kerr JFR, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;27:2013-2026.
6. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
7. Lu QL, Abel P, Foster CS, Lalani EN: Bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol 1996;27:102-110.
8. Lane DP: p53, guardian of the genome. Nature 1992;358:15-16.
9. Kernohan NM, Cox LS: Regulation of apoptosis by Bcl-2 and its related proteins: Immunochemical challenges and therapeutic implications. J Pathol 1996;179:1-3.
10. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 1996;88:386-401.
11. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997;3:614-620.
12. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148:1557-1565.
13. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
14. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
15. Apakama I, Robinson MC, Walter NM, Charlton RG, Fuller CE, Neal DE, Hamdy FC: bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996;74:1258-1262.
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
17. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992;70:523-526.
18. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991;351:453-456.
19. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-679.
20. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994; 151:1276-1280.
21. Myers RB, Oelschlager D, Srivastava S, Grizzle WE: Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 1994;25:243-248.
22. Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL, Jennings TA: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 1994;25: 92-97.
23. Heidenberg HB, Sesterhenn JP, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Srivastava S: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995;154:414-421.
24. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, Carr TW, Neal DE: p53 expression and clinical outcome in prostate cancer. Br J Urol 1993;72:778-781.
25. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84:883-887.
26. Humphrey PA, Swanson PE: Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995;191:881-887.
27. Bauer JJ, Sesterhenn IA, Mostofi FK, Mcleod DG, Srivastava S, Moul JE: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156:1511-1516.
28. Moul JW, Bettencourt M-C, Sesterhenn IA, Mostofi FK, McLeod DG, Sristava S, Bauer JJ: Protein expression of p53, bcl-2 and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996; 120:159-167.
29. Stattin P, Damber J-E, Karlberg L, Bergh A: Cell proliferation assessed by KI-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997; 157:219-222.
30. Westin P, Stattin P, Damber JE, Bergh A: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995;146:1368-1375.
31. Brown CB, Sauvageot J, Kahane H, Epstein JI: Cell proliferation and apoptosis in prostate cancer - Correlation with pathologic stage? Mod Pathol 1996;9:205-209.
32. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
33. Montironi R, Magi Galluzzi CM, Marina S, Diamanti L: Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem [Suppl] 1994;19:238-245.
34. Hall PA, Levison DA, Woods AL, Yu C-W, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-294.
35. Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG: Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994;44:91-95.
36. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC: Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994; 25:797-801.
37. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G (eds): "TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours." Berlin: Springer-Verlag, 1992.
38. Shabaik AS, Krajewski S, Burgan A, Krajewski M, Reed JC: bcl-2 proto-oncogene expression in normal, hyperplastic, and neoplastic prostate tissue. Urol Pathol 1995;3:17-27.
39. Ansari B, Coates PJ, Greenstein BD, Hall PA: In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993;170:1-8.
40. Potten CS: What is an apoptotic index measuring? A commentary. Br J Cancer 1996;74:1743-1748.
41. Montironi R, Magi-Galluzzi C, Fabris G: Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 1995;191: 873-880.
42. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122: 552-562.
43. Westin P, Brandstrom A, Damber JE, Bergh A: Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma. Br J Cancer 1995;72:140-145.
44. Harrison RF, Reynolds GM, Rowlands DC: Immunohistochemical evidence for the expression of proliferating cell nuclear antigen (PCNA) by non-proliferating hepatocytes adjacent to metastatic tumours and in inflammatory conditions. J Pathol 1993;171:115-22.
45. Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, de Vere White RW: Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 1996;27:573-580.
46. Krajewski M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576.
47. Stattin P, Damber J-E, Karlberg L, Nordgren H, Bergh A: Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 1996;24:257-264.
48. Bonkhoff H, Remberger K: Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996;28:98-106.
49. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.